Judy Ashworth (MD) has over two decades experience in clinical drug development. As Vice President, Rx Strategic Services and Chief Medical Officer at Pinney Associates, Judy supports clients developing CNS-active drugs, from traditional pharmaceuticals to psychedelics and cannabinoids, for neurologic and psychiatric indications.Judy currently serves as acting Chief Medical Officer at Ceruvia Lifesciences, supporting the development of psilocybin in AUD, OCD and headache disorders.An internist by training and graduate of UCLA School of Medicine, Judy began her drug development career as a clinical pharmacologist at Grünenthal GmbH in 2001, where she soon assumed project leadership of its abuse-deterrent formulations program. From 2006 to 2008, Judy was a visiting lecturer in Columbia University’s Department of Substance Abuse Research, concurrently participating in the Tufts Health Care Institute Program on Opioid Risk Management. In parallel, she fostered the development of safer pain management alternatives by establishing Grünenthal U.S.A.’s Center of Excellence for Abuse Liability. Along with her work at Pinney Associates, she is the Chief Medical Officer for Harm Reduction Therapeutics, a nonprofit devoted to saving lives from opioid overdose by making low-cost naloxone available as an OTC product.